Article
Restoring the 14-3-3/CRAF regulatory interaction in Noonan syndrome using molecular glues.
Proceedings of the National Academy of Sciences of the United States of America - 5 May 2026
Virta Johanna M, Vickery Holly R, Konstantinidou Markella, Crawford Mckenna C, Pennings Marloes A M, Ottmann Christian, Brunsveld Luc, Arkin Michelle R
Abstract excerpt
Noonan syndrome (NS) is the most common RASopathy, a developmental disorder that derives from dysregulation of the mitogen-activated protein kinase (MAPK) pathway. NS results from modestly activating mutations in proteins throughout the pathway. Trametinib, a MEK inhibitor, has shown promising results for certain NS complications, but NS-specific therapeutic options are lacking. CRAF activity, which is governed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.